Skip to main content

AstraZeneca (AZN.L) said on Monday it had struck a deal to buy U.S.-based drug developer CinCor Pharma Inc (CINC.O) for up to $1.8 billion to increase its stock of heart and kidney drugs.

Core to the deal is CinCor’s experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney disease.

Published by Natalie Grover in Reuters.